Takeda Pharmaceutical Half-year Profit, Revenue Improve

Takeda Pharmaceutical Company Limited (TKPHF.PK,TAK) on Thursday said its Reported operating profit increased 60.5% to 346.0 billion yen during first half of the year.

Core earnings for the first half declined 2.8% to 335.9 billion Yen and core EPS decreased 3.3% to 214 Yen per share.

Reported net profit also showed a rise of more than 100% in the first half to 183.6 billion Yen or 117 Yen per share

However, the company said its core operating profit for the current period decreased 4.3% due to divestitures and increased R&D investment.

Reported revenue for the the six-month period increased 12.8% year-over-year to 1,794.4 billion, helped by sales growth in 14 global brands.

Core revenue for the period jumped 4.4% to 1,661.4 billion.

Looking forward to the full year, Takeda expects revenue to be 3,370 billion Yen. Reported EPS is expected at 117 Yen, and Core EPS at 394 Yen for the period.

The company also has set its annual dividend at 180 Yen per share.

Further, the company announced a share buyback program of up to 100 billion Yen.

"Takeda's strong commercial portfolio and R&D pipeline are diversified across four core therapeutic areas and represent innovative and potentially transformative benefits for patients. Altogether, we believe that the combination of these growth drivers will continue to propel our business forward and help to ensure our future growth is resilient, for not just the next quarter but the next decade," commented Christophe Weber, Chief Executive Officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Luxury electric car maker Tesla Inc. has produced more than 3 million vehicles, of which 1 million in Shanghai Gigafactory, according to its founder and Chief Executive Officer Elon Musk. In a tweet on Sunday, Musk said, "Congrats Giga Shanghai on making millionth car! Total Teslas made now over 3M." King's Hawaiian is recalling its Pretzel Slider Buns, Pretzel Hamburger Buns and Pretzel Bites products as they contain one ingredient already recalled by Lyons Magnus, the U.S. Food And Drug Administration said. The Pretzel recall was initiated out of an abundance of caution after one of its supplier Lyons Magnus recently called back various nutritional and beverage products. German consumer goods maker Henkel AG & Co. reported Monday weak profit in its first half amid increasing costs, despite growth in sales. Further, the company maintained its adjusted earnings forecast for fiscal 2022, but raised outlook for organic sales growth.For fiscal 2022, the company continues to expect adjusted earnings per preferred share to decline in the range of 15 percent to 35 percent
Follow RTT